公开(公告)号：KR1020080002341A

公开(公告)日：2008-01-04

申请号：KR1020060061119

申请日：2006-06-30

Applicant: 재단법인서울대학교산학협력재단

Inventor： 신영기 ,  최윤라 ,  박영우 ,  송경 ,  이승현

IPC: A61K38/17 ,  A61K38/00 ,  A61K39/00 ,  G01N33/574

CPC classification number: A61K38/178 ,  A61K38/00 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6813 ,  A61K47/6849 ,  A61K49/0008 ,  A61K51/1027 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/732 ,  C07K2317/734 ,  C12N15/1138 ,  C12N2310/14 ,  A61K2300/00

Abstract: A method for inhibiting cancer is provided to inhibit CD24 which is expressed in most of cancers and hinder the binding between CD24 and P-selectin, so that it is useful for treating cancer by inhibiting CD24-overexpressed various cancers. The CD24-overexpressed cancer is inhibited by targeting CD24 through administration of anti-CD24 antibody to a patient, wherein the anti-CD24 antibody is prepared by specifying the amino acid sequence of SEQ ID NO:5 in CD24 sequence of SEQ ID NO:7 as an epitope, wherein the CD24-overexpressed cancers include ovarian cancer, breast cancer, small cell lung cancer, prostate cancer, pancreatic cancer, colon cancer, bladder cancer, liver cancer, small intestine cancer, large intestine cancer, cervical cancer or bile duct cancer.

Abstract translation: 提供了抑制癌症的方法，以抑制在大多数癌症中表达的CD24，并阻碍CD24和P-选择素之间的结合，从而可用于通过抑制CD24-过量表达的各种癌症来治疗癌症。 通过向患者施用抗CD24抗体来靶向CD24来抑制CD24过表达的癌症，其中通过指定SEQ ID NO：7的CD24序列中SEQ ID NO：5的氨基酸序列来制备抗CD24抗体 作为表位，其中CD24-过表达的癌症包括卵巢癌，乳腺癌，小细胞肺癌，前列腺癌，胰腺癌，结肠癌，膀胱癌，肝癌，小肠癌，大肠癌，子宫颈癌或胆管 癌症。

公开(公告)号：KR1020080040412A

公开(公告)日：2008-05-08

申请号：KR1020060108352

申请日：2006-11-03

Applicant: 재단법인서울대학교산학협력재단

Inventor： 신영기 ,  정헌순 ,  오유경 ,  이정현

IPC: C01G19/02 ,  B82B3/00

CPC classification number: C12N15/1131 ,  C12N2310/14 ,  C12N2320/31

Abstract: A composition for treating cancer is provided to show excellent cancer treating effect compared to treatment by a human papilloma virus(HPV) specific siRNA only or an anti-cancer agent only and prevent side effects caused by a highly concentrated anti-cancer agent by using a lowly concentrated anti-cancer agent. A composition for treating cervix cancer comprises a first active part including an HPV specific siRNA as an effective ingredient and a second active part including a lowly concentrated anti-cancer agent such as cisplatin, heptaplatin, carboplatin or riboplatin, wherein the HPV specific siRNA includes a sequence described as SEQ ID : NOs. 1 or 3 to 14. A method for treating cancer comprises the steps of: (a) administering an effective amount of the HPV specific siRNA at one or two times for 24 hours to a patient; and (b) administering an effective amount of the lowly concentrated anti-cancer agent to the patient for 4-7 days. Further, a concentration of the anti-cancer agent is 0.625 to 160 muM.

Abstract translation: 提供了用于治疗癌症的组合物，与仅通过人乳头状瘤病毒（HPV）特异性siRNA或抗癌剂的治疗相比，显示出优异的癌症治疗效果，并且通过使用抗癌剂，可以预防由高度浓缩的抗癌剂引起的副作用 低浓度抗癌剂。 用于治疗子宫颈癌的组合物包含包含HPV特异性siRNA作为有效成分的第一活性部分和包含低浓度抗癌药如顺铂，七铂素，卡铂或核铂的第二活性部分，其中所述HPV特异性siRNA包括 序列描述为SEQ ID：NO。 1或3至14.一种治疗癌症的方法包括以下步骤：（a）向患者施用有效量的一半或两次HPV特异性siRNA 24小时; 和（b）向患者施用有效量的低浓度抗癌剂4-7天。 此外，抗癌剂的浓度为0.625〜160μm。

公开(公告)号：KR100962301B1

公开(公告)日：2010-06-11

申请号：KR1020060108352

申请日：2006-11-03

Applicant: 재단법인서울대학교산학협력재단

Inventor： 신영기 ,  정헌순 ,  오유경 ,  이정현

IPC: C01G19/02 ,  B82B3/00

CPC classification number: C12N15/1131 ,  C12N2310/14 ,  C12N2320/31

Abstract: 본 발명은 자궁경부암을 위한 치료용 조성물에 관한 것으로, 구체적으로 자궁경부암의 원인이 되는 인간 유두종 바이러스(human papilloma virus: 이하 “HPV”라 칭함)의 특이적인 siRNA를 유효성분으로 함유하는 제 1 활성부와 항암제를 유효성분으로 함유하는 제 2 활성부로 구성된 암 치료용 조성물에 관한 것이다. 본 발명의 암 치료용 조성물은 단독으로 HPV 특이적인 siRNA 또는 항암제를 치료하는 것보다 뛰어난 암 치료 효과를 가지며, 기존의 항암제와 비교하여 저농도의 항암제를 사용함으로써 고농도의 항암제 사용으로 인한 부작용을 근절할 수 있다.
인간 유두종 바이러스, 자궁경부암, siRNA, 시스플라틴, 병용치료.

公开(公告)号：KR1020090088757A

公开(公告)日：2009-08-20

申请号：KR1020080014214

申请日：2008-02-15

Applicant: 재단법인서울대학교산학협력재단

Inventor： 신영기 ,  권미정 ,  오은설 ,  인용호 ,  고상석

IPC: C12Q1/68

CPC classification number: C12Q1/6837 ,  C12Q1/6851 ,  C12Q1/6876

Abstract: A method for treating and analyzing gene expression data is provided to totally analyze data in data base and identify standard expression gene. A method for selecting candidate standard expression gene comprises: a step of digitalizing the expression amount of gene in EST, SAGE and microarray data set; a step of selecting a gene which is expressed in different tissues with zero rate and expression amount of gene; In the digitalization of gene expression amount, the math equation 1 and 2 is used. The math equation 1 is EST gene expression amount = (the number of EST of specific gene in specific library/the number of total EST in specific library) X 1000000, and math equation 2 is SAGE gene expression amount = (the number of tag of specific gene in specific library / the number of total tag in specific library) X 1000000.

Abstract translation: 提供了一种治疗和分析基因表达数据的方法，以全面分析数据库中的数据并鉴定标准表达基因。 选择候选标准表达基因的方法包括：将EST，SAGE和微阵列数据集中的基因的表达量数字化的步骤; 选择在不同组织中表达的基因的步数为零，表达量为基因; 在基因表达量的数字化中，使用数学方程1和2。 数学方程式1是EST基因表达量=（特异性文库中特异性基因的EST数/特异性文库中的总EST数）×1000000，数学方程式2为SAGE基因表达量=（标记数 特定文库中的特异性基因/特定文库中的总标签数）×1000000。